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Abstract
Background: The standard in vitro test to assess anti-malarial activity of chemical compounds is
the [3H]hypoxanthine incorporation assay. It is a radioactivity-based method to measure DNA
replication of Plasmodium in red blood cells. The method is highly reproducible, however, the
handling of radioactive material is costly, hazardous and requires the availability of appropriate
technology and trained staff. Several other ways to evaluate in vitro anti-malarial activity do exist, all
with their own assets and limitations.
Methods: The newly developed double-antibody sandwich ELISA described here is based on the
properties of a non-overlapping pair of monoclonal antibodies directed against Plasmodium
falciparum aldolase. This glycolytic enzyme possesses some unique nucleotide sequences compared
to the human isoenzymes and has been highly conserved through evolution. Out of twenty
possibilities, the most sensitive antibody pair was selected and used to quantitatively detect parasite
aldolase in infected blood lysates.
Results: A total of 34 compounds with anti-malarial activity were tested side-by-side by ELISA and
the [3H]hypoxanthine incorporation assay. The novel ELISA provided IC50s closely paralleling those
from the radioactivity-based assay (R = 0.99, p < 0.001). At the investigated assay conditions (72 h
incubation time, parasitaemia = 0.3%), the assay was found to be reproducible and easy to perform.
Conclusion:  The newly developed ELISA presents several advantages over the comparative
method, the [3H]hypoxanthine incorporation assay. The assay is highly reproducible, less hazardous
(involves no radioactivity) and requires little and cheap technical equipment. Relatively unskilled
personnel can conduct this user-friendly assay. All this makes it attractive to be employed in
resource-poor laboratories.
Background
Several techniques exist to measure anti-malarial activity
of chemical compounds. The most commonly used
method, especially in well-equipped laboratories, is the
[3H]hypoxanthine incorporation assay [1]. This method is
highly reproducible, however, the handling of radioactive
material is costly, hazardous and quite complex and,
therefore, problematic for resource-poor locations. More-
over, radioactive material is not uniformly authorized
worldwide, limiting its application geographically. A low-
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cost alternative is the schizont maturation assay, standard-
ized by the World Health Organization. However, this test
can only be carried out by the experienced microscopist, is
very labour-intensive and prone to individual variability.
A method that is simple to establish, highly reproducible,
that requires little technical equipment and could be
applicable to a field laboratory, is the enzyme-linked
immunosorbent assay (ELISA). A few commercialized
ELISA tests are already available, targeting either Plasmo-
dium falciparum lactate dehydrogenase (pLDH) or histi-
dine-rich protein 2 (HRP2) [2-6]. Like P. falciparum
aldolase, pLDH is very much conserved between P. falci-
parum isolates [7]. It presents some unique differences to
the human LDH, and its level can be used to determine
the drug susceptibility of malaria parasites [8]. The exist-
ing commercial kits testing pLDH are suitable with an ini-
tial parasitaemia of 0.005% of cultivated or natural strains
[5]. HRP2 has recently been reported to show extensive
protein sequence diversity (mainly insertions) in all of the
analysed 75 P. falciparum isolates collected from geo-
graphically different areas [9]. Importantly, it was demon-
strated that the HRP2 protein diversity had an effect on
the sensitivities of the HRP2 detection antibodies. The
same group also reports that the aldolase protein
sequence shows no insertions by analysing 36 of the orig-
inal 75 P. falciparum isolates [10]. This prompted us to
develop a suitable double-antibody sandwich ELISA
detecting P. falciparum aldolase to evaluate anti-malarial
drug sensitivity. The newly developed aldolase ELISA was
compared to the [3H]hypoxanthine incorporation assay,
testing anti-malarial compounds such as OZ277 [11,12],
artesunate (AS), chloroquine (CQ), pyrimethamine (PYR)
and mefloquine (MEF).
Methods
Parasite cultivation
Plasmodium falciparum (NF54, Schiphol Airport, Nether-
lands) was cultivated in a modification of the medium
previously described [12,13], consisting of RPMI 1640
supplemented with 0.5% ALBUMAX® II, 25 mM HEPES,
25 mM NaHCO3 (pH 7.3), 0.36 mM hypoxanthine and
100 μg/ml neomycin. Human erythrocytes served as host
cells. Cultures were maintained at 37°C in an atmosphere
of 3% O2, 4% CO2 and 93% N2 in humidified modular
chambers. The NF54 isolate was provided by F. Hoff-
mann-LaRoche Ltd (Basel, Switzerland).
Chemicals and materials
OZ277 tosylate (MW: 565) was provided by J.L. Venner-
strom (Nebraska, USA), pyrimethamine (MW: 249) and
mefloquine hydrochloride (MW: 415) were gifts from F.
Hoffmann-LaRoche (Basel, Switzerland), artesunate
(MW: 384) was donated by Guilin Pharma Corp. (Guilin
Guangxi, China) and chloroquine diphosphate (MW:
516) was purchased from Sigma. Further anti-malarial
compounds were obtained from the NGBS malaria pro-
gramme, a consortium formed by the Novartis Institute
for Tropical Diseases, the Genomics Institute of the
Novartis Research Foundation, the Biomedical Primate
Research Center and the Swiss Tropical Institute (com-
pounds were provided by M. Rottmann, Swiss Tropical
Institute Basel, Switzerland). All anti-malarial compounds
were dissolved in dimethylsulfoxide (DMSO) at 10 mg/
ml, except chloroquine, which was dissolved in water. The
stock solutions were kept at 4°C for a maximum of six
months. Dilutions were prepared from the stock solution
in hypoxanthine-free culture medium immediately before
use. [3H]hypoxanthine was purchased from Amersham
Bioscience (Buckinghamshire, UK).
The recombinant P. falciparum aldolases P41/5 (S359T)
and P41/7 (K365N) were obtained from lambdaGT11
phage expression libraries constructed with genomic DNA
of the K1 isolate of P. falciparum and were kindly provided
by H. Döbeli, (F. Hoffmann-La Roche Ltd, Basel, Switzer-
land) [14,15].
Generation of hybridoma cell lines producing anti-
Plasmodium falciparum aldolase antibodies
Anti-P. falciparum aldolase antibodies were identified by
immunoprecipitation with Protein A-sepharose (GE
Healthcare) in the soluble fraction of an infected culture.
Hybridoma strains P.41-1/2-7, P.41-2/3-7, P.41-4/1-12,
P.41-8/11-8 and P.41-24/10-11 [16] were grown in
Iscove's modified Dulbecco's medium (Invitrogen) sup-
plemented with 10%v/v FBS (Gibco), 1%v/v Penicillin-
Streptomycin (Gibco), 1%v/v L-Glutamine (Gibco) in cell
culture flasks, at 37°C, 5%CO2. Monoclonal antibodies
(mAbs) were purified from hybridoma supernatant on
ProteinG following the manufacturer's instructions (AKT-
AprimeTM, Amersham Biosciences, using HiTrapTM Pro-
tein G (GE Healthcare)). The detection antibody was
coupled to horseradish peroxidase (HRP, SIGMA) as
described by Nakane and Kawaoi [17]. The capture anti-
body was stored at 4°C in PBS supplemented with 0.02%
NaN3. The HRP detection antibody was kept at 4°C in a
PBS-50% glycerol solution supplemented with 10 mg/ml
BSA.
In vitro growth-inhibition assay
Plasmodium falciparum (NF54) growth was assessed by
measuring the incorporation of the nucleic acid precursor
[3H]hypoxanthine [18]. IC50 values were earlier found to
be 0.91 ± 0.12 ng/ml for OZ277, 1.6 ± 0.1 for artesunate,
5.1 ± 0.8 for chloroquine, 5.8 ± 0.2 for mefloquine [11]
and 5.6 ± 0.5 ng/ml for pyrimethamine [19]. Infected
erythrocytes (100 μl per well with 2.5% haematocrit and
0.3% parasitaemia) were added to each drug titrated in
100 μl duplicates over a 64-fold range. After 48 h incuba-
tion, 0.5 μCi of [3H]hypoxanthine in 50 μl medium was
added and plates were incubated for an additional 24 h.
Parasites were harvested onto glass-fiber filters and radio-Malaria Journal 2009, 8:226 http://www.malariajournal.com/content/8/1/226
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activity was counted using a Betaplate liquid scintillation
counter (Wallac, Zurich). The results were recorded as
counts per minute (cpm) per well at each drug concentra-
tion and expressed as a percentage of the untreated con-
trols.
Double antibody sandwich ELISA
96-well microtiter plates (Maxisorp, Nunc) were coated
with 100 μl/well of the capture antibody P.41-24/10-11
(5 μg/ml in PBS) overnight at 4°C. The plates were then
saturated with 200 μl/well of 1% BSA in PBS-Tween20
(0.05%) for 1 hour at 37°C. 50 μl of the test samples were
then added and incubated 1 h at 37°C. Then, 50 μl/well
of the detection antibody P.41-2/3-7 - HRP (0.8 μg/ml)
were added, and the plates incubated 1 h in the dark at
room temperature. Finally, 100 μl/well of the substrate
(Tetramethylbenzidine) solution was added and the reac-
tion stopped after 5 min with 100 μl 1 N H2SO4. The opti-
cal densities (ODs) were measured at 450 nm by an ELISA
plate reader (Biotrak visible plate reader, Amersham Phar-
macia Biotech). Between each incubation step, the plates
were washed four times with PBS-Tween (0.05%
Tween20).
Statistics
Fifty percent inhibitory concentrations (IC50s) were deter-
mined in XLfit from IDBS by a 4 parameter logistic model.
After controlling the normal distribution of the data, a
correlation coefficient between the results obtained side-
by-side by the two methods was determined by a standard
Pearson's correlation analysis (Stata 9.1) and a Bland-Alt-
man plot was performed, testing the agreement between
them (Stata 9.1).
Table 1: IC50s for OZ277, AS, CQ, PYR and MEF obtained from the aldolase ELISA and the [3H]hypoxanthine method with the P. 
falciparum strain NF54
Anti-malarial compound Drug assay (n = 3) IC 50 ± SD (ng/ml) [3H]hypoxanthine data (ng/ml) from Vennerstrom et al, 
2004; Maerki et al, 2006
OZ277 [3H]hypoxanthine 0.36 (± 0.03) 0.91 (± 0.12)
OZ277 Aldolase ELISA 0.63 (± 0.18)
AS [3H]hypoxanthine 0.91(± 0.32) 1.6 (± 0.1)
AS Aldolase ELISA 1.6 (± 0.3)
CQ [3H]hypoxanthine 3.8 (± 0.5) 5.1 (± 0.8)
CQ Aldolase ELISA 5.3 (± 0.7)
PYR [3H]hypoxanthine 3.8 (± 0.6) 5.6 (± 0.5)
PYR Aldolase ELISA 7.9 (± 2.1)
MEF [3H]hypoxanthine 4.3 (± 1.0) 5.8 (± 0.2)
MEF Aldolase ELISA 6.9 (± 0.5)
Geometric mean IC50s with 95% CIs for OZ277, artesunate (AS), chloroquine (CQ), pyrimethamine (PYR) and mefloquine (MEF) determined side-
by-side by [3H]hypoxanthine assay and aldolase ELISA. Previously published IC50s for [3H]hypoxanthine assay are given for comparison. Mean values 
shown from n = 3 independent experiments.Malaria Journal 2009, 8:226 http://www.malariajournal.com/content/8/1/226
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Results
Five anti-recombinant aldolase monoclonal antibodies
were tested both as capture as well as detection antibodies
(HRP-labeled) in a double-antibody sandwich ELISA tar-
geting P. falciparum recombinant aldolase P41/7 (highest
concentration was 10 μg/ml). Ultimately, the antibody
pair P.41-24/10-11; P.41-2/3-7+HRP was selected, show-
ing a good specificity (steep curve) and the broadest
dynamic range (OD span). When P. falciparum cultures
(NF54) of e.g. initial parasitaemias of 0.3% or 0.03% were
incubated for 72 hours and then lysed and analysed by
ELISA, the observed ODs were 2.3 and 0.23, with a back-
ground signal (uninfected blood sample) of about 0.04.
Having obtained such a solid signal to background ratio
of > 50 at the higher starting parasitaemia (0.3%), and
since 0.3% is the typical parasitaemia employed for the
hypoxanthine assay, an ELISA with five anti-malarial com-
pounds was performed under these conditions, side-by-
side with a [3H]hypoxanthine incorporation assay. After
48 h, [3H]hypoxanthine dissolved in assay medium was
added to the hypoxanthine incorporation assay, whereas
the ELISA received the same volume of hypoxanthine-free
assay medium. The geometric mean IC50s ± SDs obtained
from the two methods are shown in Table 1, together with
the expected [3H]hypoxanthine assay values.
An excellent correlation coefficient of R = 0.991 (P <
0.001) was found when additional 29 anti-malarial com-
pounds were tested and both log IC50s of all compounds,
including OZ277, AS, CQ, PY and MEF, plotted (Figure
1).
To test the agreement between ELISA and [3H]hypoxan-
thine incorporation assay, the difference in log IC50s
obtained from the two methods were plotted against their
mean value in a Bland-Altman plot (Figure 2). The two
methods were found to agree, as > 96% of the values lie in
acceptable broad limits of agreement (-0.85 to 0.32).
Discussion
The novel ELISA provides IC50s closely paralleling those
from the standard [3H]hypoxanthine incorporation assay
(Table 1), with P.41-24/10-11 as capture antibody and
P.41-2/3-7-HRP as detection antibody targeting P. falci-
parum aldolase. The excellent correlation between IC50s
determined by the [3H]hypoxanthine incorporation assay
and by aldolase ELISA (R = 0.991, P < 0.001; Figure 1) was
further confirmed by the Bland-Altman plot (Figure 2),
showing a general trend of the two methods to agree
nicely. The limits of agreement correlate with the findings
of Noedl et al who compared the [3H]hypoxanthine incor-
poration assay and the HRP2 ELISA [20]. Interestingly, the
aldolase ELISA tends in all cases to measure slightly higher
IC50s than the [3H]hypoxanthine incorporation assay.
However, this observation should have no impact on the
power of the assay.
Aldolase is commonly used as a pan-malaria antigen in
rapid diagnostic tests (RDTs) [21]. It can, therefore, not be
ruled out that our monoclonal antibodies could cross-
react with aldolase from other Plasmodium species. This
should be kept in mind when embarking in future drug
susceptibility testing efforts in species-overlapping zones.
Aldolase- and pLDH-based RDTs are reported to be less
sensitive than HRP2-based tests, due to the transient pres-
ence in blood of the first [21,22]. However, since the low-
est parasitaemia tested in this study (0.03%) did result in
a solid signal to background ratio of ~5, the sensitivity is
not expected to be an issue for drug sensitivity testing in
the field. Furthermore, the aldolase amino acid sequence
is highly conserved, preventing detection failures, as seen
in the case of HRP2 [9]. The aldolase ELISA presents no
drawbacks or assets over pLDH-based assays.
Conclusion
The novel aldolase ELISA assay is highly reproducible, less
hazardous than the [3H]hypoxanthine incorporation
assay and requires little and cheap technical equipment.
Relatively unskilled personnel can conduct this user-
friendly assay. All this makes it attractive to be employed
in resource-poor laboratories.
The fact that the P. falciparum aldolase has been highly
conserved during evolution [10] renders aldolase an anti-
body target of choice for the analysis of field isolates. It
Correlation of log IC50s obtained from the aldolase ELISA  and the [3H]hypoxanthine method with the P. falciparum  strain NF54 Figure 1
Correlation of log IC50s obtained from the aldolase 
ELISA and the [3H]hypoxanthine method with the P. 
falciparum strain NF54. 34 compounds were tested by 
ELISA and [3H]hypoxanthine incorporation (n = 1) with the 
P. falciparum strain NF54. The log IC50 in nM (or ng/ml for the 
standard compounds) from [3H]hypoxanthine incorporation 
is plotted against the log IC50 from ELISA, for each com-
pound. (n = 34, correlation coefficient (R) = 0.991 and p-
value < 0.001).
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also provides a considerable advantage over the HRP2
ELISA, since the HRP2 gene sequence is showing an exten-
sive diversity, altering the sensitivity of some commercial
diagnostic tests.
However, before proceeding to drug susceptibility testing
in endemic countries, further investigations with more
parasite isolates should be performed in order to deter-
mine the lowest measurable parasitaemia (sensitivity) of
the aldolase ELISA as well as if the here described mono-
clonal antibodies cross-react with aldolase from other
Plasmodium species.
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